Press ReleaseJan | 18 | 2023
Researchers Discover Why Only Some People Experience Long-Term Benefits from Peanut Allergy Treatments
- New research reveals why oral immunotherapy for peanut allergy can lead to sustained tolerance in some individuals but only transient tolerance in others
- In patients with sustained tolerance, neutralizing antibodies block specific regions of the peanut allergen, which prevents the binding of other antibodies that trigger allergic reactions
BOSTON – Food allergies are caused by IgE antibodies that are generated by the immune system and bind to allergens such as peanuts, triggering a reaction that in extreme cases can be potentially life-threatening.
New research by scientists at Massachusetts General Hospital (MGH), University of Paris Saclay, and the National Institute of Environmental Health Sciences (NIEHS) reveals why oral immunotherapy, which treats food allergies through incremental increases in consumption of the allergen, can lead to sustained tolerance in some individuals but only transient tolerance in others.
The findings, which are published in the Journal of Clinical Investigation, may help investigators improve allergy treatments so that all patients can benefit.
Ingestion of allergens through oral immunotherapy as treatment for food allergies increases blood levels of allergen-specific IgG neutralizing antibodies that can block IgE-mediated allergic reactions. Only a subset of individuals with peanut allergy develop sustained responses to oral immunotherapy, however.
“We hypothesized that in people with long-lived tolerance after peanut oral immunotherapy, allergen-specific protective antibodies may have unique properties—for example in how they recognize the allergen—that may result in their ability to more effectively neutralize the allergen on exposure and therefore result in tolerance,” says senior author Sarita U. Patil, MD, an assistant in Medicine at MGH and an Assistant Professor at Harvard Medical School.
To investigate, Patil and her colleagues analyzed blood collected from pediatric and adult participants of two peanut oral immunotherapy clinical trials at MGH, and they applied a fluorescence-based method developed previously by Patil to identify cells in the blood that make antibodies against the peanut allergen.
The team discovered that neutralizing antibodies from patients with sustained tolerance after immunotherapy block certain regions of the peanut allergen, therefore disrupting the ability of IgE antibodies to bind. Antibodies from patients with only transient tolerance after immunotherapy did not block these same regions.
A team of researchers at NIEHS led by Geoffrey Mueller, PhD was able to specifically identify these important regions. “We were able to use X-ray crystallography to see some of the first complex structures describing how human antibodies interact with peanut allergens,” says Mueller. “After studying allergens for so many years, it was very gratifying and an important new development.”
“Our paper is the first to describe neutralizing antibodies in allergy, describe their mechanism, and identify tools to assess their efficacy in preventing allergy IgE antibodies from binding to the allergen,” says Patil.
“This provides a new path for both therapeutic and diagnostic test development. As a therapeutic, neutralizing antibodies may be able to provide clinical protection. From a diagnostic perspective, we may be able to predict about future tolerance development based on the presence or absence of these antibodies in patients.”
Additional co-authors include Nicole A. LaHood (co-first author), Jungki Min (co-first author), Tarun Keswani, Crystal M. Richardson, Kwasi Amoako, Jingjia Zhou, Orlee Marini-Rapoport, Bernard Hervé, Stéphane Hazebrouck, Wayne G. Shreffler, J. Christopher Love, Anna Pomes, Lars C. Pedersen, and Geoffrey A. Mueller.
This work was funded by NIH, NIAID grant 5R01AI155630 (SUP). This research was supported in part by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences, ZIA-ES102906 (GAM), and 1ZIC-ES102645 (LCP).
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In July 2022, Mass General was named #8 in the U.S. News & World Report list of "America’s Best Hospitals." MGH is a founding member of the Mass General Brigham healthcare system.
Centers and Departments
Check out the Mass General Research Institute blog
Bench Press highlights the groundbreaking research and boundary-pushing scientists working to improve human health and fight disease.
Support Research at Mass General
Your gift helps fund groundbreaking research aimed at understanding, treating and preventing human disease.